Changes in the Expression of TBP-2 in Response to Histone Deacetylase Inhibitor Treatment in Human Endometrial Cells

Int J Mol Sci. 2021 Jan 31;22(3):1427. doi: 10.3390/ijms22031427.

Abstract

Histone deacetylase inhibitors (HDACi) induce apoptosis preferentially in cancer cells by caspase pathway activation and reactive oxygen species (ROS) accumulation. Suberoylanilide hydroxamic acid (SAHA), a HDACi, increases apoptosis via altering intracellular oxidative stress through thioredoxin (TRX) and TRX binding protein-2 (TBP-2). Because ROS accumulation, as well as the redox status determined by TBP-2 and TRX, are suggested as possible mechanisms for endometriosis, we queried whether SAHA induces apoptosis of human endometrial cells via the TRX-TBP-2 system in endometriosis. Eutopic endometrium from participants without endometriosis, and ectopic endometrium from patients with endometriosis, was obtained surgically. Human endometrial stromal cells (HESCs) and Ishikawa cells were treated with SAHA and cell proliferation was assessed using the CCK-8 assay. Real-time PCR and Western blotting were used to quantify TRX and TBP-2 mRNA and protein expression. After inducing oxidative stress, SAHA was applied. Short-interfering TRX (SiTRX) transfection was performed to see the changes after TRX inhibition. The mRNA and protein expression of TBP-2 was increased with SAHA concentrations in HESCs significantly. The mRNA TBP-2 expression was decreased after oxidative stress, upregulated by adding 2.5 μM of SAHA. The TRX/TBP-2 ratio decreased, apoptosis increased significantly, and SiTRX transfection decreased with SAHA. In conclusion, SAHA induces apoptosis by modulating the TRX/TBP-2 system, suggesting its potential as a therapeutic agent for endometriosis.

Keywords: apoptosis; endometriosis; oxidative stress; suberoylanilide hydroxamic acid; thioredoxin.

MeSH terms

  • Apoptosis / drug effects*
  • Cell Proliferation / drug effects
  • Endometrium / drug effects
  • Female
  • Histone Deacetylase Inhibitors / pharmacology*
  • Humans
  • Nuclear Proteins / drug effects*
  • Nuclear Proteins / genetics
  • Oxidative Stress / drug effects
  • Reactive Oxygen Species / metabolism
  • TATA Box Binding Protein-Like Proteins / drug effects*
  • TATA Box Binding Protein-Like Proteins / genetics
  • Thioredoxins / drug effects*
  • Thioredoxins / genetics
  • Vorinostat / pharmacology*

Substances

  • Histone Deacetylase Inhibitors
  • Nuclear Proteins
  • Reactive Oxygen Species
  • TATA Box Binding Protein-Like Proteins
  • TBPL2 protein, human
  • TXN protein, human
  • Thioredoxins
  • Vorinostat